Day One Biopharmaceuticals to acquire Mersana Therapeutics for $285m.

Day One Biopharmaceuticals, a biopharmaceutical company, agreed to acquire Mersana Therapeutics, a clinical-stage biopharmaceutical company, for $285m. “This acquisition will add a potential game-changing new medicine to the Day One portfolio and, if approved, will broaden our opportunities for patient impact and for continued growth and value creation,” Jeremy Bender, Day One CEO.